Senzime för investerare
Senzime develops, manufactures and markets CE- and FDA-cleared patient monitoring systems. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.
Presentation of Senzime’s Q4 2022 report
February 1, 14:00 CET
The presentation can be followed live at Fourth Quarter Report Presentation
Extraordinary General Meeting, February 16
The shareholders in Senzime AB (publ) are convened to an extraordinary general meeting on Thursday 16 February 2023.
Preliminary financial information for the development of the fourth quarter 2022 and trading update